AXGN
AxoGen, Inc.
AXGN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AXGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
AXGN's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AXGN PE Valuation
AXGN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AXGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
AXGN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AXGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | — |
| Q3 2026 | -$0.65 | -$0.59 |
| Q2 2026 | -$0.68 | -$0.57 |
| Q1 2026 | -$0.64 | -$0.48 |
| Q4 2025 | -$0.34 | -$0.11 |
| Q3 2025 | -$0.06 | +$0.25 |
| Q2 2025 | -$0.11 | +$0.26 |
| Q1 2025 | -$0.16 | +$0.33 |
| Q4 2024 | -$0.23 | +$0.28 |
AXGN lost $0.65 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AXGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $75.8M | +26% |
| Q2 2026 | $69.7M | +23% |
| Q1 2026 | $61.5M | +27% |
| Q4 2025 | $59.9M | +21% |
| Q3 2025 | $60.1M | +24% |
| Q2 2025 | $56.7M | +18% |
| Q1 2025 | $48.6M | +17% |
| Q4 2024 | $49.4M | +15% |
AXGN's revenue has grown year over year for 18 quarters in a row: $76M last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | -1.9 points |
| Q2 2026 | -3.1% | -6 points |
| Q1 2026 | -4.6% | -1.2 points |
| Q4 2025 | -16% | -20 points |
| Q3 2025 | 3.2% | +3.8 points |
| Q2 2025 | 3% | +3.8 points |
| Q1 2025 | -3.4% | +7.6 points |
| Q4 2024 | 4.1% | +12 points |
AXGN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AXGN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AXGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.1M | +789% |
| Q2 2026 | $6.3M | -9.7% |
| Q1 2026 | -$1.2M | +$12.2M |
| Q4 2025 | $1.8M | -78% |
| Q3 2025 | $1.7M | -48% |
| Q2 2025 | $7M | +115% |
| Q1 2025 | -$13.4M | -$245K |
| Q4 2024 | $8.1M | +$9.7M |
AXGN has burned cash in most quarters: $22M over the past year, about seven times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AXGN on cash flow, with more consistent year-over-year improvement.
AXGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +8.2M shares |
| 1 year | +25% | +12.4M shares |
| 3 years | +43% | +18.5M shares |
| 5 years | +48% | +20.1M shares |
| Available history | +55% | +21.8M shares |
AXGN has 62M diluted shares, up 25% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $639,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AXGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AXGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 4.7x | High |
| Q4 2024 | 6.3x | High |
AXGN's net debt is about 2.3 years of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AXGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.0 | Neutral |
| Stochastic | 83.0 | Overbought |
AXGN's weekly RSI is 66 (neutral) and its Stochastic is 83 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AXGN PE vs Healthcare Sector
AXGN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AXGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.1 | 29% above |
| 20 week MA | $44.2 | 25% above |
| 50 week MA | $39.2 | 41% above |
| 100 week MA | $27.8 | 100% above |
| 200 week MA | $18.3 | 203% above |
AXGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AXGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.6 | $17.7 | -4.8% |
| 2021 | $17.7 | $9.82 | -45% |
| 2022 | $9.82 | $9.94 | +1.2% |
| 2023 | $9.94 | $6.83 | -31% |
| 2024 | $6.83 | $16.7 | +144% |
| 2025 | $16.7 | $32.8 | +97% |
| 2026 YTD | $32.8 | $55.4 | +69% |
AXGN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.